Xin Tai Medical (02291) announced that its Supervisory Board has recommended the appointment of Wang Yong as Supervisor and Chairman of the second-term Supervisory Board. This nomination follows standard corporate governance procedures for board succession planning. The proposed leadership transition demonstrates the company's commitment to maintaining robust oversight structures while ensuring continuity in governance functions. Wang Yong's expected dual role as both Supervisor and Chairman would consolidate board leadership responsibilities under a single executive.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。